Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15172181 | 0.86 | AKR1C3 (0.49) | CA1CA2AKR1C3 | |
| SCHEMBL8563961 | 0.77 | MTNR1A (0.46) | CA1CA2ALDH1A1 | |
| SCHEMBL8563958 | 0.77 | MTNR1A (0.46) | CA1CA2ALDH1A1 | |
| SCHEMBL8563956 | 0.77 | MTNR1A (0.46) | CA1CA2ALDH1A1 | |
| SCHEMBL22265257 | 0.76 | CA1 (0.55) | CA1CA2PSEN1PSEN2APH1B | |
| SCHEMBL6374701 | 0.76 | CA1 (0.45) | CA1CA2ALDH1A1PSEN1PSEN2 | |
| SCHEMBL7762830 | 0.76 | CA1 (0.45) | CA1CA2ALDH1A1PSEN1PSEN2 | |
| SCHEMBL31443393 | 0.76 | CA1 (0.55) | CA1CA2PSEN1PSEN2APH1B | |
| SCHEMBL29593055 | 0.76 | CA1 (0.45) | CA1CA2ALDH1A1PSEN1PSEN2 | |
| SCHEMBL30137235 | 0.76 | CA1 (0.41) | CA1CA2ALDH1A1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | CA1 189/4885CA2 673/4885ALDH1A1 350/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | CA1 219/4885CA2 1138/4885ALDH1A1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.